Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAKEN: Muvalaplin in Adults With Elevated Lipoprotein(a) and High CV Risk
NCT05563246Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of muvalaplin in elevated lipoprotein(a) (Lp(a)), sponsored by Eli Lilly and Company. Started Nov 2022; status: completed.
02
Drugs
muvalaplin
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT05563246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563246.